Reagila CapsuleS
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of acute relapses of schizophrenia and maintenance therapy in adults.
Dosage (summary)
Starting dose: 1.5 mg once daily, max: 6 mg/day.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Not recommended during pregnancy; use effective contraception. Breastfeeding not advised.
Key Drug Interactions
- Strong/moderate CYP3A4 inhibitors
- Strong/moderate CYP3A4 inducers
Contraindications
- Hypersensitivity to active substance or excipients
- Concomitant use with strong/moderate CYP3A4 inhibitors/inducers
Common side effects
- Akathisia
- Parkinsonism
- Weight gain
Counselling Points
- Monitor for weight changes
- Caution with driving and machinery
- Report any signs of tardive dyskinesia
Serious warnings
- Suicidal ideation and behavior
- Neuroleptic malignant syndrome
- Risk of cerebrovascular accidents
Important Disclaimer
The Reagila CapsuleS professional information leaflet below is the property of Adcock Ingram Limited and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
